TapewireFind a company

person · Reporting owner

van Houte Hans

Disclosed activity across 1 company

Tapewire entity
26681
SEC CIK
0001817217

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Nurix Therapeutics, Inc.NRIX · Entity 1156Chief Financial OfficerAugust 04, 2026August 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Nurix Therapeutics, Inc.

Report date August 04, 2026 · Filed August 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect40,166 Ending reported balance After 2026-08-04 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-08-04 · Sale · Disposed 1,794 · Balance 43,133

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Row 2 · 2026-08-04 · Sale · Disposed 2,967 · Balance 40,166

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3: Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

F3: Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 30, 2024 Filed Jan 30, 2024 23:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,671 $7.99 $13,351.62
Disclosure

SEC source: 0001549595-24-000009 · wk-form4_1706658780.xml · nonDerivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,145

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $7.93 and the highest price at which shares were sold was $8.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000009 · wk-form4_1706658780.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000009 · wk-form4_1706658780.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 20, 2023 Filed Dec 21, 2023 22:19 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 3,541 $10.00 $35,420.98
Disclosure

SEC source: 0001549595-23-000066 · wk-form4_1703197177.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,930

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $10.00 and the highest price at which shares were sold was $10.03. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
December 19, 2023 Filed Dec 20, 2023 21:55 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 10,906 $10.00 $109,092.72
Disclosure

SEC source: 0001549595-23-000064 · wk-form4_1703109315.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,471

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $10.0000 and the highest price at which shares were sold was $10.0200. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 31, 2023 Filed Nov 1, 2023 20:41 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,080 $5.20 $5,613.19
Disclosure

SEC source: 0001549595-23-000060 · wk-form4_1698871254.xml · nonDerivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,377

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $5.04 and the highest price at which shares were sold was $5.28. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:41 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000060 · wk-form4_1698871254.xml · derivative · entry 5

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:41 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,886 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000060 · wk-form4_1698871254.xml · derivative · entry 4

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,975

Underlying: Common Stock · 2,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:41 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000060 · wk-form4_1698871254.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,457

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:41 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000060 · wk-form4_1698871254.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,457

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2023 Filed Aug 1, 2023 20:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,245 $9.65 $12,020.10
Disclosure

SEC source: 0001209191-23-043982 · doc4.xml · nonDerivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,571

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.61 and the highest price at which shares were sold was $9.82. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043982 · doc4.xml · derivative · entry 5

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,886 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043982 · doc4.xml · derivative · entry 4

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,861

Underlying: Common Stock · 2,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043982 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043982 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 01, 2023 Filed May 2, 2023 20:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 721 $9.88 $7,120.81
Disclosure

SEC source: 0001209191-23-026522 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,930

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
April 30, 2023 Filed May 2, 2023 20:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,886 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-026522 · doc4.xml · derivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,747

Underlying: Common Stock · 2,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2023 Filed May 2, 2023 20:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-026522 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,651

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2023 Filed Feb 15, 2023 21:13 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 24,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-009711 · doc4.xml · derivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
February 14, 2023 Filed Feb 15, 2023 21:13 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 88,900 $0.00 Strike: $10.83 $0.00
Disclosure

SEC source: 0001209191-23-009711 · doc4.xml · derivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,900

Underlying: Common Stock · 88,900 shares

Expires 2033-02-13

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:17 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,886 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-005908 · doc4.xml · derivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,633

Underlying: Common Stock · 2,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:17 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 924 $11.78 $10,884.35
Disclosure

SEC source: 0001209191-23-005908 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,765

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.60 and the highest price at which shares were sold was $12.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:17 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-005908 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,689

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 31, 2022 Filed Nov 1, 2022 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 739 $12.88 $9,518.69
Disclosure

SEC source: 0001209191-22-055146 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,803

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.76 and the highest price at which shares were sold was $12.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 30, 2022 Filed Nov 1, 2022 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,886 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-055146 · doc4.xml · derivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,519

Underlying: Common Stock · 2,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2022 Filed Nov 1, 2022 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-055146 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 09, 2022 Filed Aug 10, 2022 20:17 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 120,000 $0.00 Strike: $18.50 $0.00
Disclosure

SEC source: 0001209191-22-045195 · doc4.xml · derivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2032-08-08

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning September 9, 2022 until the option is fully vested on August 9, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
August 01, 2022 Filed Aug 2, 2022 21:46 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 752 $15.67 $11,783.84
Disclosure

SEC source: 0001209191-22-043962 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,656

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $15.32 and the highest price at which shares were sold was $16.01. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 30, 2022 Filed Aug 2, 2022 21:46 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,886 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-043962 · doc4.xml · derivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,405

Underlying: Common Stock · 2,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2022 Filed Aug 2, 2022 21:46 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-043962 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,408

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 31, 2022 Filed Jun 1, 2022 20:57 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 68,333 $0.00 Strike: $0.84 $0.00
Disclosure

SEC source: 0001209191-22-033200 · doc4.xml · derivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 68,333 shares

Expires 2026-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested.

Read SEC document
May 31, 2022 Filed Jun 1, 2022 20:57 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 68,333 $0.84 $57,399.72
Disclosure

SEC source: 0001209191-22-033200 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,522

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 02, 2022 Filed May 3, 2022 23:03 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 697 $11.75 $8,189.75
Disclosure

SEC source: 0001209191-22-026890 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,189

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Read SEC document
April 30, 2022 Filed May 3, 2022 23:03 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,886 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-026890 · doc4.xml · derivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,291

Underlying: Common Stock · 2,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2022 Filed May 3, 2022 23:03 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,886 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-026890 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 19, 2022 Filed Jan 21, 2022 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 46,177 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-004406 · doc4.xml · derivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,177

Underlying: Common Stock · 46,177 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 19, 2022 Filed Jan 21, 2022 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 103,894 $0.00 Strike: $19.49 $0.00
Disclosure

SEC source: 0001209191-22-004406 · doc4.xml · derivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,894

Underlying: Common Stock · 103,894 shares

Expires 2032-01-18

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 19, 2022 until the option is fully vested on January 19, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
February 24, 2021 Filed Feb 25, 2021 21:18 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,829 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-21-014307 · doc4.xml · derivative · entry 7

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,504

Underlying: Common Stock · 1,829 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F4 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
February 24, 2021 Filed Feb 25, 2021 21:18 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 13,197 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001209191-21-014307 · doc4.xml · derivative · entry 6

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,136

Underlying: Common Stock · 13,197 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning June 10, 2019 until the option is fully vested on May 10, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
February 24, 2021 Filed Feb 25, 2021 21:18 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 20,393 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0001209191-21-014307 · doc4.xml · derivative · entry 5

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,027

Underlying: Common Stock · 20,393 shares

Expires 2028-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 2, 2018 until the option is fully vested on January 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
February 24, 2021 Filed Feb 25, 2021 21:18 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 35,419 $39.90 $1,413,218.10
Disclosure

SEC source: 0001209191-21-014307 · doc4.xml · nonDerivative · entry 4

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
February 24, 2021 Filed Feb 25, 2021 21:18 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,829 $7.26 $13,278.54
Disclosure

SEC source: 0001209191-21-014307 · doc4.xml · nonDerivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
February 24, 2021 Filed Feb 25, 2021 21:18 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 13,197 $1.86 $24,546.42
Disclosure

SEC source: 0001209191-21-014307 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
February 24, 2021 Filed Feb 25, 2021 21:18 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 20,393 $1.20 $24,471.60
Disclosure

SEC source: 0001209191-21-014307 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 23:04 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 3,913 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0001209191-21-013353 · doc4.xml · derivative · entry 5

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,420

Underlying: Common Stock · 3,913 shares

Expires 2028-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F4 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 2, 2018 until the option is fully vested on January 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 23:04 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,417 $0.00 Strike: $0.84 $0.00
Disclosure

SEC source: 0001209191-21-013353 · doc4.xml · derivative · entry 4

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,333

Underlying: Common Stock · 1,417 shares

Expires 2026-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option is fully vested.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 23:04 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 5,330 $39.93 $212,839.16
Disclosure

SEC source: 0001209191-21-013353 · doc4.xml · nonDerivative · entry 3

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $39.90 and the highest price at which shares were sold was $40.03. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 23:04 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,913 $1.20 $4,695.60
Disclosure

SEC source: 0001209191-21-013353 · doc4.xml · nonDerivative · entry 2

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,330

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 23:04 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,417 $0.84 $1,190.28
Disclosure

SEC source: 0001209191-21-013353 · doc4.xml · nonDerivative · entry 1

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,417

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
February 18, 2021 Filed Feb 22, 2021 21:09 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 13,583 $0.00 Strike: $0.84 $0.00
Disclosure

SEC source: 0001209191-21-012668 · doc4.xml · derivative · entry 7

van Houte Hans · CIK 0001817217 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,750

Underlying: Common Stock · 13,583 shares

Expires 2026-01-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F7 · derivative.exercise_date: The option is fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.